Why the study?
What are the cardiovascular and renal actions of the novel synthetic vasonatrin peptide (VNP) in vitro and in vivo?
What are the cardiovascular and renal actions of the novel synthetic vasonatrin peptide (VNP) in vitro and in vivo?
Vasonatrin peptide is a novel synthetic chimera that combines the beneficial venodilating and natriuretic properties of CNP and ANP while adding unique arterial vasodilating effects.
VNP's combined actions in animals support chimeric natriuretic peptide design; leaves open translation to human cardiovascular therapy.
This study reports the cardiovascular and renal actions of a novel and newly synthesized 27-amino acid peptide termed vasonatrin peptide (VNP). VNP is a chimera of atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP). This synthetic peptide possesses the 22-amino acid structure of CNP, which is a cardiovascular selective peptide of endothelial origin and is structurally related to ANP. VNP also possesses the five-amino acid COOH terminus of ANP. The current study demonstrates both in vitro and in vivo that VNP possesses the venodilating actions of CNP, the natriuretic actions of ANP, and unique arterial vasodilating actions not associated with either ANP or CNP.
No takes yet. Share an insight, caveat, or question.
Wei et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: